Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

Abstract Background While immune checkpoint inhibitors (ICIs) occasionally cause immune-related adverse events (irAEs) in various organs, the prevalence of irAEs and potential risk factors have not been clarified. We identified irAE predictive factors and examined the relationship between the effect...

Full description

Bibliographic Details
Main Authors: Yuki Yoshikawa, Michio Imamura, Masami Yamauchi, C. Nelson Hayes, Hiroshi Aikata, Wataru Okamoto, Yoshihiro Miyata, Morihito Okada, Noboru Hattori, Kazuhiko Sugiyama, Yukio Yoshioka, Shigeaki Toratani, Masaaki Takechi, Tatsuo Ichinohe, Tsutomu Ueda, Sachio Takeno, Tsuyoshi Kobayashi, Hideki Ohdan, Jun Teishima, Michihiro Hide, Yasushi Nagata, Yoshiki Kudo, Koji Iida, Kazuaki Chayama
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Cancer
Subjects:
Immune checkpoint inhibitors
Immune-related adverse events
Immune-related liver injury
Programmed death 1
Cytotoxic T-lymphocyte antigen 4
Combination therapy
Online Access:https://doi.org/10.1186/s12885-022-10327-7

Internet

https://doi.org/10.1186/s12885-022-10327-7

Similar Items